Bio-Rad Laboratories (BIO-B) Non-Current Deferred Tax Liability (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at $881.8 million in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability rose 4.88% year-over-year to $881.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $881.8 million (up 4.88% YoY) and the FY2025 annual result came in at $1.1 billion, up 14.26% from the prior year.
• Non-Current Deferred Tax Liability slipped to $881.8 million in Q1 2026 per BIO-B's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $2.0 billion in Q1 2022 and bottomed at $840.8 million in Q1 2025.
• The 5-year median for Non-Current Deferred Tax Liability is $1.4 billion (2023), against an average of $1.3 billion.
• The widest annual swing landed in 2022, when Non-Current Deferred Tax Liability slumped 58.41%; it then rose 14.26% in 2025.
• Tracing BIO-B's Non-Current Deferred Tax Liability over 5 years: stood at $1.8 billion in 2022, then slipped by 7.16% to $1.6 billion in 2023, then tumbled by 43.59% to $927.2 million in 2024, then climbed by 14.26% to $1.1 billion in 2025, then dropped by 16.76% to $881.8 million in 2026.
• Per Business Quant, the three latest BIO-B Non-Current Deferred Tax Liability figures stand at $881.8 million (Q1 2026), $1.1 billion (Q4 2025), and $872.6 million (Q3 2025).

Peer Comparison